By Denny Jacob
LifeMD shares surged 22% after announcing plans to offer access to semaglutide, which is marketed as Wegovy to treat obesity, through NovoCare Pharmacy.
Shares were trading around $7.49. The stock is down 49% on the year.
The virtual primary care services provider said the addition of direct access to Wegovy provides a brand-name GLP-1 option at a recently reduced self-pay cost of $499 a month. It added that all doses of Wegovy are available in a pen device to eligible LifeMD patients who are uninsured or whose insurance doesn't cover prescription weight-loss medications.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 29, 2025 08:53 ET (12:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.